FDA Clears Vertex's Gene Therapy for Sickle Cell in Children Aged Two and Up
VRTX sits 37% above its 52-week low of $362.5.
Summary
The FDA has approved Vertex Pharmaceuticals' gene therapy, Casgevy, for treating sickle cell disease in children as young as two years old. This significantly expands the market for Casgevy, which was previously approved only for patients aged 12 and older. The approval was granted rapidly under the FDA's fast-track program, underscoring the therapy's importance for this vulnerable patient group. This development strengthens Vertex's position in gene therapy and offers a one-time treatment option for a severe inherited blood disorder at an earlier stage. It builds on recent positive momentum, including strong first-quarter results and another FDA acceptance for a different drug.
At the time of this announcement, VRTX was trading at $496.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.4B. The 52-week trading range was $362.50 to $507.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.